XOMA Royalty Corporation (XOMA)
(Delayed Data from NSDQ)
$29.24 USD
+0.32 (1.11%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $29.25 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
XOMA Royalty Corporation [XOMA]
Reports for Purchase
Showing records 181 - 200 ( 331 total )
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 13
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
We assume coverage of XOMA with a Buy rating and $9.00 price target
Provider: Roth Capital Partners, Inc.
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
We Believe XOMA 358 Could Reduce Pipeline Risk Through Diversification. Reiterate OUTPERFORM and $14 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
EYEGUARD-US Initiation Decreases Regulatory Risk for Gevokizumab, in Our View; Reiterate OUTPERFORM and $14 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
October and Remaining 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
EYEGUARD-US Initiation Decreases Regulatory Risk for Gevokizumab, in Our View; Reiterate OUTPERFORM and $14 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept 8
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
September and Remaining 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 25
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES AND HEALTH CARE - 2014 LSMAC Day 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals - August and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Q2 Financials: Cash Runway Covers Multiple Value Drivers, Including a Major Catalyst on the Horizon, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES AND HEALTH CARE-The Week Ahead in Life Sciences - Upcoming Events for the Week of July 21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
July and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Even with a Delay, We Anticipate EYEGUARD-B Data Release by the End of Q3; Reiterate OUTPERFORM and $14 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
Even with a Delay, We Anticipate EYEGUARD-B Data Release by the End of Q3; Reiterate OUTPERFORM and $14 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Royalty Corporation
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES AND HEALTH CARE - The Week Ahead in Life Sciences - Upcoming Events for the Week of June 30
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L